Chen et al. find that a specific B cell subset is associated with immunotherapy resistance in bladder cancer. IGLL5+ B cells interact with HEVs through IGLL5-LTβR signaling, leading to the impairment of TLSs formation in humanized mouse models. This interaction presents a promising therapeutic target for overcoming immunotherapy resistance in bladder cancer.
Chen et al. find that a specific B cell subset is associated with immunotherapy resistance in bladder cancer. IGLL5+ B cells interact with HEVs through IGLL5-LTβR signaling, leading to the impairment of TLSs formation in humanized mouse models. This interaction presents a promising therapeutic target for overcoming immunotherapy resistance in bladder cancer.